NZ720766A - Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers - Google Patents

Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Info

Publication number
NZ720766A
NZ720766A NZ720766A NZ72076614A NZ720766A NZ 720766 A NZ720766 A NZ 720766A NZ 720766 A NZ720766 A NZ 720766A NZ 72076614 A NZ72076614 A NZ 72076614A NZ 720766 A NZ720766 A NZ 720766A
Authority
NZ
New Zealand
Prior art keywords
treatment
combination therapy
pharmaceutically active
cancers
mdm2 inhibitor
Prior art date
Application number
NZ720766A
Other languages
English (en)
Inventor
Sean Caenepeel
Jude Canon
Paul Hughes
Jonathan D Oliner
Richard J Rickles
Anne Y Saiki
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to NZ758548A priority Critical patent/NZ758548A/en
Publication of NZ720766A publication Critical patent/NZ720766A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NZ720766A 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers NZ720766A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ758548A NZ758548A (en) 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902717P 2013-11-11 2013-11-11
PCT/US2014/065034 WO2015070224A2 (en) 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Publications (1)

Publication Number Publication Date
NZ720766A true NZ720766A (en) 2022-02-25

Family

ID=52001089

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ720766A NZ720766A (en) 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
NZ758548A NZ758548A (en) 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ758548A NZ758548A (en) 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Country Status (33)

Country Link
US (3) US20160287569A1 (enExample)
EP (2) EP4039256A1 (enExample)
JP (5) JP2016535795A (enExample)
KR (3) KR20220167335A (enExample)
CN (2) CN112933236A (enExample)
AP (1) AP2016009243A0 (enExample)
AU (3) AU2014346354A1 (enExample)
BR (1) BR112016010564A2 (enExample)
CA (1) CA2930244A1 (enExample)
CL (1) CL2016001131A1 (enExample)
CY (1) CY1125358T1 (enExample)
DK (1) DK3068393T5 (enExample)
EA (2) EA036942B1 (enExample)
ES (1) ES2916721T3 (enExample)
HR (1) HRP20220718T1 (enExample)
HU (1) HUE059351T2 (enExample)
IL (2) IL245568B (enExample)
LT (1) LT3068393T (enExample)
MA (1) MA39094B1 (enExample)
MX (6) MX378969B (enExample)
MY (1) MY192088A (enExample)
NZ (2) NZ720766A (enExample)
PH (1) PH12016500871A1 (enExample)
PL (1) PL3068393T3 (enExample)
PT (1) PT3068393T (enExample)
RS (1) RS63348B9 (enExample)
SG (1) SG10201902429PA (enExample)
SI (1) SI3068393T1 (enExample)
SM (1) SMT202200241T1 (enExample)
TN (1) TN2016000176A1 (enExample)
UA (1) UA120750C2 (enExample)
WO (1) WO2015070224A2 (enExample)
ZA (1) ZA201603342B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
MX378969B (es) * 2013-11-11 2025-03-11 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
EP3341023A1 (en) * 2015-08-28 2018-07-04 Novartis AG Combination therapy using pi3k inhbitor and mdm2 inhibitor
AU2016314082B2 (en) * 2015-08-28 2019-07-25 Novartis Ag Mdm2 inhibitors and combinations thereof
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
KR20210043499A (ko) 2018-05-25 2021-04-21 카토스 테라퓨틱스, 인크. 골수증식성 신생물 치료 방법
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN110963958B (zh) * 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
EP3927344A4 (en) * 2018-12-11 2023-01-18 Kartos Therapeutics METHODS AND COMPOSITIONS FOR THE TREATMENT OF AN EYE CONDITION
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物
CN112294965B (zh) 2019-07-26 2023-03-14 苏州亚盛药业有限公司 Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021254277A1 (en) * 2020-06-15 2021-12-23 Ascentage Pharma (Suzhou) Co., Ltd. Microsuspension of an mdm2 inhibitor and therapeutic applications thereof
TW202227082A (zh) * 2020-08-12 2022-07-16 美商施維雅製藥有限公司 用於治療癌症之組合療法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115089585A (zh) * 2022-08-05 2022-09-23 中国科学院大学宁波华美医院 Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
WO2024254156A1 (en) * 2023-06-05 2024-12-12 Kartos Therapeutics, Inc. Treatment of endometrial cancer with mdm2 inhibitors
WO2025098488A1 (zh) * 2023-11-09 2025-05-15 深圳艾欣达伟医药科技有限公司 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
AU2005295441B2 (en) 2004-10-18 2009-04-23 Amgen, Inc. Thiadiazole compounds and methods of use
WO2007084391A2 (en) 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
US7705018B2 (en) 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
US7919498B2 (en) 2007-03-23 2011-04-05 Amgen Inc. Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors
AU2008231304B2 (en) 2007-03-23 2011-05-12 Amgen Inc. Heterocyclic compounds and their uses
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
CA2689092C (en) 2007-06-07 2013-01-15 Amgen Inc. Raf kinase modulators and methods of use
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
JP5530422B2 (ja) 2008-04-07 2014-06-25 アムジエン・インコーポレーテツド 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
US20110263647A1 (en) 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
WO2010096314A1 (en) 2009-02-18 2010-08-26 Amgen Inc. INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
MX2011009796A (es) 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
EA201270013A1 (ru) 2009-06-25 2012-06-29 Амген Инк. Гетероциклические соединения и их применение
WO2010151791A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
MX2011013667A (es) 2009-06-25 2012-03-06 Amgen Inc Compuestos heterociclicos y sus usos.
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
HRP20150104T1 (xx) 2009-09-11 2015-03-13 Amgen, Inc. N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-thienil)-1-ftalazinamin za primjenu u tretmanu kancera rezistentnog na antimitotiäśke agense
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
KR20120031734A (ko) * 2010-09-27 2012-04-04 삼성전자주식회사 급성 골수성 백혈병 환자의 시타라빈 민감성을 예측하기 위한 키트 및 방법
EP2670396A1 (en) * 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
WO2013144923A1 (en) 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
CA2901696C (en) 2013-02-19 2021-04-13 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
US20150031642A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i
MX378969B (es) * 2013-11-11 2025-03-11 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.

Also Published As

Publication number Publication date
JP2021004259A (ja) 2021-01-14
PL3068393T3 (pl) 2022-10-03
US10881648B2 (en) 2021-01-05
CN112933236A (zh) 2021-06-11
JP2019142916A (ja) 2019-08-29
MX2019009853A (es) 2019-10-14
AU2020201321B2 (en) 2022-03-10
WO2015070224A2 (en) 2015-05-14
JP2016535795A (ja) 2016-11-17
LT3068393T (lt) 2022-08-10
SG10201902429PA (en) 2019-04-29
MA39094B1 (fr) 2020-06-30
AP2016009243A0 (en) 2016-05-31
ES2916721T3 (es) 2022-07-05
RS63348B1 (sr) 2022-07-29
IL245568A0 (en) 2016-06-30
DK3068393T3 (da) 2022-06-13
EA201690980A1 (ru) 2016-09-30
ZA201603342B (en) 2025-04-30
BR112016010564A2 (pt) 2017-10-10
US20190290630A1 (en) 2019-09-26
RS63348B9 (sr) 2022-10-31
IL245568B (en) 2021-09-30
EP4039256A1 (en) 2022-08-10
WO2015070224A3 (en) 2015-08-13
CN105934255A (zh) 2016-09-07
MY192088A (en) 2022-07-26
KR20210119550A (ko) 2021-10-05
CA2930244A1 (en) 2015-05-14
MA39094A1 (fr) 2018-07-31
KR102473485B1 (ko) 2022-12-01
AU2022201495A1 (en) 2022-03-24
EP3068393B9 (en) 2022-07-20
PH12016500871A1 (en) 2016-07-04
EA202092456A2 (ru) 2021-05-31
MX378969B (es) 2025-03-11
AU2020201321A1 (en) 2020-03-12
DK3068393T5 (da) 2022-08-22
MX2016006025A (es) 2016-12-02
SI3068393T1 (sl) 2022-11-30
MX391859B (es) 2025-03-12
MX2022012320A (es) 2022-10-27
TN2016000176A1 (en) 2017-10-06
SMT202200241T1 (it) 2022-09-14
EP3068393A2 (en) 2016-09-21
IL285646A (en) 2021-09-30
MX2020001550A (es) 2022-04-26
KR20220167335A (ko) 2022-12-20
NZ758548A (en) 2022-02-25
MX393610B (es) 2025-03-24
UA120750C2 (uk) 2020-02-10
HUE059351T2 (hu) 2022-11-28
MX2020013670A (es) 2022-09-30
US20160287569A1 (en) 2016-10-06
EA036942B1 (ru) 2021-01-18
US20220280495A1 (en) 2022-09-08
JP6972274B2 (ja) 2021-11-24
AU2014346354A1 (en) 2016-05-26
EA202092456A3 (ru) 2021-09-30
JP2023033414A (ja) 2023-03-10
PT3068393T (pt) 2022-06-14
KR20160074012A (ko) 2016-06-27
MX2022008175A (es) 2022-08-15
CL2016001131A1 (es) 2017-04-17
CY1125358T1 (el) 2024-09-20
JP2022009805A (ja) 2022-01-14
HRP20220718T1 (hr) 2022-09-30
KR102305351B1 (ko) 2021-09-24
EP3068393B1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
NZ720766A (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
CY1123661T1 (el) Κρυσταλλικη μορφη ενος αναστολεα της mdm2
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
HK1244483A1 (zh) (s)-n-(5 - ((r)-2-(2，5-二氟苯基)吡咯烷-1-基) - 吡唑并[1，5-a ]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐
EA201001412A1 (ru) Ингибиторы киназы pim и способы их применения
JO2886B1 (en) Useful compounds in the inhibition of CHK1
MX2009010929A (es) Terapias de combinacion que comprenden inhibidores de quinoxalina de pi3k-alfa para uso en el tratamiento del cancer.
TW200718689A (en) 2-Amino-quinazolin-5-ones
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
MX2015012386A (es) Inhibidores de la cinasa cdk9.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
WO2017117386A8 (en) Methods of treating cancer using network brakes
AU2013208087A8 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof
PL397923A1 (pl) Nowe zastosowanie medyczne substancji 5-(3-chlorofenylo)-4-(4-metylofenylo)-2-(morfolin-4-ylometylo)-2,4-dihydro-3H-1,2,4-triazolo-3-tionu
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
AR104811A1 (es) Formulación oral de liberación sostenida
RU2015111612A (ru) Фармацевтическая композиция на основе 3-(3,5-Диметилпиразол-1-ил)имидазо[1,2-b][1,2,4,5]тетразина в качестве противоопухолевого средства

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2023 BY COMPUTER PACKAGES INC

Effective date: 20221117

LAPS Patent lapsed